Sugi Predict

Sugi Predict / Targets / IRAK3

IRAK3

Interleukin-1 receptor-associated kinase 3 · Q9Y616 · IRAK3 on Sugi Atlas →

10,366 patent compounds predicted against IRAK3, 7,155 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
R-406 R-406 (SCHEMBL1200144) 1.00 2/20
Fostamatinib Fostamatinib (SCHEMBL1201371) 1.00 2/20
SCHEMBL1383686 SCHEMBL1383686 0.89 2/20
R-406 R-406 (SCHEMBL1222514) 0.83 2/20
SCHEMBL1380946 SCHEMBL1380946 0.67 2/20
SCHEMBL1197041 SCHEMBL1197041 0.65 2/20
SCHEMBL1083288 SCHEMBL1083288 0.62 2/20
SCHEMBL823917 SCHEMBL823917 0.59 2/20
SCHEMBL1384343 SCHEMBL1384343 0.58 2/20
SCHEMBL191238 SCHEMBL191238 0.54 2/20
SCHEMBL724133 SCHEMBL724133 0.53 2/20
SCHEMBL1384407 SCHEMBL1384407 0.52 2/20
SCHEMBL1381667 SCHEMBL1381667 0.51 2/20
SCHEMBL1382922 SCHEMBL1382922 0.51 2/20
SCHEMBL20079 SCHEMBL20079 0.49 2/20
SCHEMBL731471 SCHEMBL731471 0.46 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL525239) 0.46 2/20
SCHEMBL736302 SCHEMBL736302 0.39 2/20
SCHEMBL1441871 SCHEMBL1441871 0.37 2/20
SCHEMBL1441873 SCHEMBL1441873 0.37 2/20

Clinical trials — most relevant to IRAK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis PHASE4NOT_YET_RECRUITING
Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation PHASE4ACTIVE_NOT_RECRUITING
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF PHASE3COMPLETED
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms PHASE1/PHASE2RECRUITING
Cilostazol in Parkinson's Disease PHASE2NOT_YET_RECRUITING
Leniolisib for Immune Dysregulation in PIDs PHASE2ACTIVE_NOT_RECRUITING
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis PHASE2COMPLETED
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia PHASE1NOT_YET_RECRUITING
Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC PHASE1WITHDRAWN
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers PHASE1COMPLETED
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined EARLY_PHASE1RECRUITING
RNA Cloning and Visualization in Human Atherosclerosis nanCOMPLETED
MicroRNAs and Cytokines in Peri-Implantitis Tissue nanUNKNOWN
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry Bad Cholesterol in the Blood nanCOMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus nanUNKNOWN
Role of IL 12 and IL 23 as Potential Biomarkers in Diagnosis of Early Crohn's Disease nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk nanWITHDRAWN
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis nanCOMPLETED
The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population nanRECRUITING
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases nanUNKNOWN
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear nanUNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Analysis of Donor Biopsy Tissue Samples at the Time of Kidney Transplant nanCOMPLETED
Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients nanCOMPLETED
Immune Interactions in Severe Asthma nanCOMPLETED
Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients: Impact of Ferretin and D -Dimer. nanUNKNOWN
Role of ST2 in Acute Pancreatitis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a IRAK3 binder may also engage these)

ProteinNameSimilarity
Q8K4B2 — 0.970 Q8K4B2 →
Q3SZJ2 — 0.960 Q3SZJ2 →
P58801 — 0.960 P58801 →
RIPK2 Receptor-interacting serine/threonine-protein kinase 2 0.948 landscape →
Q92565 — 0.930 Q92565 →
P83900 — 0.929 P83900 →
Q80T74 — 0.929 Q80T74 →
STK11 Serine/threonine-protein kinase STK11 0.928 landscape →
Q8IUI8 — 0.928 Q8IUI8 →
Q01887 — 0.927 Q01887 →
Q9NR64 — 0.927 Q9NR64 →
P24786 — 0.926 P24786 →
Q9WTK7 — 0.926 Q9WTK7 →
Q5IS37 — 0.926 Q5IS37 →
Q9JI74 — 0.925 Q9JI74 →
Q96CT2 — 0.925 Q96CT2 →
Q0GGW5 — 0.925 Q0GGW5 →
Q80ZF8 — 0.925 Q80ZF8 →
Q5IFJ9 — 0.924 Q5IFJ9 →
P21580 — 0.924 P21580 →
Q9Z2L7 — 0.924 Q9Z2L7 →
Q4R8W3 — 0.924 Q4R8W3 →
P34925 — 0.923 P34925 →
Q91987 — 0.923 Q91987 →
NTRK3 NT-3 growth factor receptor 0.923 landscape →
D4AE59 — 0.923 D4AE59 →
P54277 — 0.923 P54277 →
Q0VC93 — 0.923 Q0VC93 →
PTAR1 Protein prenyltransferase alpha subunit repeat-containing protein 1 0.922 landscape →
O60242 — 0.921 O60242 →